Clinical trial
Imatinib Mesylate in Combination With Docetaxel for Advanced…
NCT00216112 · Daniela Matei, MD, Other · Completed
Key facts
| NCT number | NCT00216112 |
|---|---|
| Title | Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer |
| Official title | Imatinib Mesylate (Gleevec®, STI571) in Combination With Docetaxel (Taxotere) for the Treatment of Advanced, Platinum-Refractory Ovarian Cancer and Primary Peritoneal Carcinomatosis: Hoosier Oncology Group GYN03-62 |
| Lead sponsor | Daniela Matei, MD, Other |
| Collaborators | Novartis Pharmaceuticals Industry Sanofi Walther Cancer Institute |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | Imatinib Mesylate, Docetaxel |
| Enrollment | 23 |
| Start date | Dec 1, 2003 |
| Primary completion | Oct 1, 2005 |
| Completion | Jul 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | Feb 19, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: